SG11201808592PA - Method for selection of high m6p recombinant proteins - Google Patents
Method for selection of high m6p recombinant proteinsInfo
- Publication number
- SG11201808592PA SG11201808592PA SG11201808592PA SG11201808592PA SG11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new jersey
- human lysosomal
- cranbury
- march
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Water Supply & Treatment (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Bioreactor) 600 605 613 (Protein Capturing System) (Chromatography System) 617 609 (Final Product Adjustment) (Chromatography System) => => => 603 (Filtration System) 607 611 (Viral Kill) (Viral Kill) FIG. 6 615 (Filtration System) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/173059 Al 5 October 2017 (05.10.2017) WIPO I PCT 111111111111110111011111111111010111110 0101111101111111111111110111111111110111111 (51) International Patent Classification: C12N 9/26 (2006.01) (21) International Application Number: PCT/US2017/024981 (22) International Filing Date: 30 March 2017 (30.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/315,400 30 March 2016 (30.03.2016) US 62/457,584 10 February 2017 (10.02.2017) US 15/473,994 30 March 2017 (30.03.2017) US (71) Applicant: AMICUS THERAPEUTICS, INC. [US/US]; 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). (72) Inventors: DO, Hung V.; 1 Cedarbrook Drive, Cranbury, New Jersey 08512 (US). GOTSCHALL, Russell; 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). (74) Agent: ALEGRIA, Rory P.; Servilla Whitney LLC, 33 Wood Avenue South, Suite 830, Iselin, New Jersey 08830 (US). — (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: METHOD FOR SELECTION OF HIGH M6P RECOMBINANT PROTEINS (57) : Methods for the production, capturing and purification of recombinant human lysosomal proteins are described. Such recombinant human lysosomal proteins can have high content of mannose-6-phosphate residues. Also described are pharmaceutical compositions comprising such recombinant human lysosomal proteins, as well as methods of treatment and uses of such recombin- ant human lysosomal proteins. W O 20 1717 / 305 9 Al
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315400P | 2016-03-30 | 2016-03-30 | |
| US201762457584P | 2017-02-10 | 2017-02-10 | |
| US15/473,994 US10227577B2 (en) | 2016-03-30 | 2017-03-30 | Method for selection of high M6P recombinant proteins |
| PCT/US2017/024981 WO2017173059A1 (en) | 2016-03-30 | 2017-03-30 | Method for selection of high m6p recombinant proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808592PA true SG11201808592PA (en) | 2018-10-30 |
Family
ID=58640993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808592PA SG11201808592PA (en) | 2016-03-30 | 2017-03-30 | Method for selection of high m6p recombinant proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10227577B2 (en) |
| JP (3) | JP7046003B2 (en) |
| KR (3) | KR102343162B1 (en) |
| AU (2) | AU2017239640B2 (en) |
| BR (1) | BR112018070189A2 (en) |
| CA (1) | CA3019354A1 (en) |
| CL (1) | CL2018002767A1 (en) |
| IL (2) | IL262060B (en) |
| MX (3) | MX2018011951A (en) |
| PE (1) | PE20190127A1 (en) |
| SG (1) | SG11201808592PA (en) |
| WO (1) | WO2017173059A1 (en) |
| ZA (2) | ZA201807184B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017239641A1 (en) * | 2016-03-30 | 2018-10-18 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| JP7046003B2 (en) * | 2016-03-30 | 2022-04-01 | アミカス セラピューティックス インコーポレイテッド | Method for selecting high M6P recombinant protein |
| EP3568152A1 (en) * | 2017-01-10 | 2019-11-20 | Amicus Therapeutics, Inc. | Recombinant alpha-galactosidase a for treatment of fabry disease |
| WO2018213340A1 (en) * | 2017-05-15 | 2018-11-22 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase |
| MX2022002774A (en) * | 2019-09-06 | 2022-06-14 | Amicus Therapeutics Inc | Method for capturing and purification of biologics. |
| EP3871687A1 (en) * | 2020-02-27 | 2021-09-01 | eleva GmbH | Enzyme replacement therapy for treating pompe disease |
| WO2023150387A1 (en) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
| TW202400212A (en) * | 2022-05-05 | 2024-01-01 | 美商阿米庫斯醫療股份有限公司 | Methods for treating pompe disease |
| WO2024119070A1 (en) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Methods for treating late onset pompe disease in pediatric patients |
| WO2024119091A1 (en) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Fexamethods for treating infantile-onset pompe disease in pediatric patients |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| US4985445A (en) | 1988-02-12 | 1991-01-15 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitors and novel compounds |
| US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| US5011829A (en) | 1989-06-02 | 1991-04-30 | G. D. Searle & Co. | Pharmaceutical composition and method of inhibiting virus |
| US5103008A (en) | 1989-08-17 | 1992-04-07 | Monsanto Company | Compound, N-butyl-deoxynojirimycin-6-phosphate |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US20020073438A1 (en) * | 1995-08-02 | 2002-06-13 | Reuser Arnold J. | Methods of purifying human acid alpha-glucosidase |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US20020013953A1 (en) * | 1995-08-02 | 2002-01-31 | Reuser Arnold J. | Compositions and methods for treating enzyme deficiency |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
| EP1030839B1 (en) | 1997-11-10 | 2004-02-04 | G.D. SEARLE & CO. | Use of alkylated iminosugars to treat multidrug resistance |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| EP2020438B1 (en) | 1998-12-07 | 2018-04-11 | Genzyme Corporation | Treatment of pompe's disease |
| ES2311921T3 (en) | 1999-02-12 | 2009-02-16 | United Therapeutics Corporation | N- (8,8,8-TRIFLUOROOCTIL) 1-5, -DIDESOXI-1,5-IMINO-D-GLUCITOL TO TREAT INFECTIONS BY HEPATITIS VIRUSES. |
| CA2378776A1 (en) | 1999-07-26 | 2001-02-01 | G.D. Searle & Co. | Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases |
| US6642038B1 (en) | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| WO2001097829A2 (en) | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| EP3449934B1 (en) | 2000-07-18 | 2020-05-20 | Duke University | Treatment of glycogen storage disease type ii |
| CN1638739A (en) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | Compound for treating assuetude disturbance |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| WO2002087510A2 (en) | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2003032907A2 (en) | 2001-10-16 | 2003-04-24 | Rxkinetix, Inc. | High-concentration protein formulations and method of manufacture |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US7658916B2 (en) | 2002-04-05 | 2010-02-09 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density |
| ES2545619T3 (en) | 2003-01-31 | 2015-09-14 | The Mount Sinai School Of Medicine Of New York University | Combination therapy to treat protein deficiency disorders |
| FR2861991B1 (en) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | USE OF GLUCOSIDASE INHIBITORS FOR MUCOVISCIDOSE THERAPY |
| CA2556245A1 (en) * | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| JP4914224B2 (en) | 2004-02-10 | 2012-04-11 | バイオマリン ファーマシューティカル インコーポレイテッド | Acid α-glucosidase and its fragments |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| BRPI0612928A2 (en) | 2005-05-17 | 2010-12-07 | Amicus Therapeutics Inc | METHOD FOR INCREASING THE ACTIVITY OF AN (ALPHA) -GLUCOSITY ENZYME IN A CELL AND METHOD FOR TREATING POMPE'S DISEASE |
| CA2669347A1 (en) | 2006-11-13 | 2008-05-29 | Zystor Therapeutics, Inc. | Methods for treating pompe disease |
| WO2008112525A2 (en) | 2007-03-09 | 2008-09-18 | Link Medicine Corporation | Treatment of lysosomal storage diseases |
| US9056101B2 (en) | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2009066069A1 (en) | 2007-11-21 | 2009-05-28 | Summit Corporation Plc | Treatment of protein folding disorders |
| WO2009075815A1 (en) | 2007-12-07 | 2009-06-18 | Duke University | Immunomodulating gene therapy |
| SI2946785T1 (en) * | 2008-02-12 | 2019-02-28 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| AU2009223125A1 (en) | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for Pompe disease |
| JP2011512876A (en) | 2008-03-12 | 2011-04-28 | アミカス セラピューティックス インコーポレイテッド | Treatment of Pompe disease with specific pharmacological chaperones and monitoring of treatment with surrogate markers |
| US20110237538A1 (en) | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| US20100119502A1 (en) | 2008-11-11 | 2010-05-13 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
| CN103432566A (en) | 2008-12-16 | 2013-12-11 | 建新公司 | Oligosaccharide-protein conjugates |
| BRPI1010517A2 (en) | 2009-04-09 | 2017-01-31 | Amicus Therapeutics Inc | methods for prevention and / or treatment of lysosomal storage diseases |
| ES2569514T3 (en) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| CN102712914A (en) * | 2009-09-29 | 2012-10-03 | 根特大学 | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
| WO2011109600A1 (en) | 2010-03-05 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| EP2622088A2 (en) * | 2010-09-29 | 2013-08-07 | Oxyrane UK Limited | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
| JP2014513952A (en) | 2011-04-22 | 2014-06-19 | ジェンザイム・コーポレーション | Modified acid alpha glucosidase with enhanced processing |
| WO2013013017A2 (en) | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| KR102076585B1 (en) | 2011-12-22 | 2020-02-12 | 센토제너 아이피 게엠베하 | Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
| JP6236406B2 (en) | 2012-03-07 | 2017-11-22 | アミカス セラピューティックス インコーポレイテッド | High concentration α-glucosidase composition for the treatment of Pompe disease |
| CN104379162B (en) | 2012-03-15 | 2017-03-15 | 奥克西雷恩英国有限公司 | For treating method and the material of fluffy Pei Shi diseases |
| EP2844279B1 (en) | 2012-05-03 | 2020-12-09 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of pompe disease |
| AU2013273473B2 (en) | 2012-06-06 | 2016-05-26 | Consiglio Nazionale Delle Ricerche | Allosteric chaperones and uses thereof |
| CN114540327A (en) | 2014-09-30 | 2022-05-27 | 阿米库斯治疗学公司 | High strength acidic alpha-glucosidase with enhanced carbohydrate |
| JP7046003B2 (en) * | 2016-03-30 | 2022-04-01 | アミカス セラピューティックス インコーポレイテッド | Method for selecting high M6P recombinant protein |
-
2017
- 2017-03-30 JP JP2018551350A patent/JP7046003B2/en active Active
- 2017-03-30 CA CA3019354A patent/CA3019354A1/en active Pending
- 2017-03-30 KR KR1020187030848A patent/KR102343162B1/en active IP Right Grant
- 2017-03-30 KR KR1020217041615A patent/KR102455821B1/en active IP Right Grant
- 2017-03-30 IL IL262060A patent/IL262060B/en unknown
- 2017-03-30 PE PE2018001915A patent/PE20190127A1/en unknown
- 2017-03-30 SG SG11201808592PA patent/SG11201808592PA/en unknown
- 2017-03-30 BR BR112018070189-0A patent/BR112018070189A2/en unknown
- 2017-03-30 WO PCT/US2017/024981 patent/WO2017173059A1/en active Application Filing
- 2017-03-30 AU AU2017239640A patent/AU2017239640B2/en active Active
- 2017-03-30 KR KR1020227035616A patent/KR20220145918A/en not_active Application Discontinuation
- 2017-03-30 US US15/473,994 patent/US10227577B2/en active Active
- 2017-03-30 MX MX2018011951A patent/MX2018011951A/en unknown
- 2017-03-30 IL IL295551A patent/IL295551A/en unknown
-
2018
- 2018-09-28 MX MX2022014532A patent/MX2022014532A/en unknown
- 2018-09-28 CL CL2018002767A patent/CL2018002767A1/en unknown
- 2018-09-28 MX MX2022014533A patent/MX2022014533A/en unknown
- 2018-10-26 ZA ZA2018/07184A patent/ZA201807184B/en unknown
-
2019
- 2019-01-18 US US16/252,519 patent/US11441138B2/en active Active
-
2020
- 2020-10-23 ZA ZA2020/06604A patent/ZA202006604B/en unknown
-
2022
- 2022-03-22 JP JP2022044814A patent/JP7436545B2/en active Active
- 2022-09-12 US US17/931,351 patent/US20230079225A1/en active Pending
- 2022-10-27 AU AU2022259797A patent/AU2022259797B2/en active Active
-
2024
- 2024-02-08 JP JP2024017546A patent/JP2024063015A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7046003B2 (en) | 2022-04-01 |
| KR20180128945A (en) | 2018-12-04 |
| US20230079225A1 (en) | 2023-03-16 |
| KR102343162B1 (en) | 2021-12-23 |
| JP2019509754A (en) | 2019-04-11 |
| IL295551A (en) | 2022-10-01 |
| JP2022101545A (en) | 2022-07-06 |
| IL262060A (en) | 2018-11-29 |
| AU2017239640A1 (en) | 2018-10-25 |
| MX2022014532A (en) | 2022-12-13 |
| JP7436545B2 (en) | 2024-02-21 |
| BR112018070189A2 (en) | 2019-02-19 |
| PE20190127A1 (en) | 2019-01-17 |
| KR20220145918A (en) | 2022-10-31 |
| US11441138B2 (en) | 2022-09-13 |
| AU2022259797B2 (en) | 2024-08-08 |
| WO2017173059A1 (en) | 2017-10-05 |
| KR102455821B1 (en) | 2022-10-18 |
| MX2022014533A (en) | 2022-12-13 |
| US20170335301A1 (en) | 2017-11-23 |
| MX2018011951A (en) | 2019-02-13 |
| KR20210157477A (en) | 2021-12-28 |
| AU2017239640B2 (en) | 2022-07-28 |
| ZA201807184B (en) | 2021-02-24 |
| IL262060B (en) | 2022-09-01 |
| AU2022259797A1 (en) | 2022-12-01 |
| CA3019354A1 (en) | 2017-10-05 |
| JP2024063015A (en) | 2024-05-10 |
| US20190382742A1 (en) | 2019-12-19 |
| US10227577B2 (en) | 2019-03-12 |
| ZA202006604B (en) | 2023-04-26 |
| CL2018002767A1 (en) | 2019-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201806002SA (en) | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201807134RA (en) | Transposon system and methods of use | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression |